Compare WS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WS | NBTX |
|---|---|---|
| Founded | 1955 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2023 | 2018 |
| Metric | WS | NBTX |
|---|---|---|
| Price | $35.39 | $35.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $42.50 | $36.00 |
| AVG Volume (30 Days) | ★ 396.2K | 80.4K |
| Earning Date | 03-25-2026 | 03-31-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $3,093,300,000.00 | N/A |
| Revenue This Year | $16.77 | $58.17 |
| Revenue Next Year | $2.69 | N/A |
| P/E Ratio | $27.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.22 | $4.93 |
| 52 Week High | $49.17 | $57.14 |
| Indicator | WS | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 43.42 |
| Support Level | $34.33 | $30.15 |
| Resistance Level | $36.96 | $38.29 |
| Average True Range (ATR) | 1.30 | 2.57 |
| MACD | 0.40 | -0.17 |
| Stochastic Oscillator | 91.38 | 9.47 |
Worthington Steel Inc is a processor of carbon flat-rolled steel, a producer of laser-welded solutions, and a provider of electrical steel laminations. The company has manufacturing facilities across the United States, Canada, China, India, Germany and Mexico. It buys coils of steel from primary steel producers and processes them to precise type, thickness, length, width, shape, and surface quality required by customer specifications. The company's product lines and processing capabilities include; carbon flat-rolled steel processing, electrical steel laminations, and tailor welded products. Geographically, the company generates a majority of its revenue from the United States followed by Canada, Mexico, and other regions.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.